About Prescription Drug Pricing
Prescription drugs should be affordable — but patients increasingly face challenges getting medication at fair prices. California’s hospitals are committed to ensuring the availability of lifesaving and life-changing medication. More than 180 California hospitals participate in the federal 340B Drug Pricing Program, which provides discount drugs to low-income patients, while many others participate in group purchasing organizations to lower costs. Solutions to rising drug prices must address drivers of cost, like supply shortages and lack of competition, and increase transparency for drug manufacturers.
CMS Announces Reduced Coinsurance Amounts for Part B Drugs, Medicare to Pay Difference to Providers
The Centers for Medicare & Medicaid Services (CMS) announced that Medicare will reduce the beneficiary coinsurance amount for 34 Part B prescription drugs between $1 and $618 per average dose from Oct. 1-Dec. 31, 2023.
CMS Announces First Drugs for Medicare Drug Price Negotiation Program
The Centers for Medicare & Medicaid Services (CMS) announced the first 10 drugs covered under Medicare Part D selected for the Medicare Drug Price Negotiation Program.
CHA Issues Summary of Medicaid Drug Rebate Program Proposed Rule
CHA has issued a members-only summary, prepared by Health Policy Alternatives, Inc., of a proposed rule to implement policies in the Medicaid Drug Rebate Program related to legislative requirements addressing drug misclassification, as well as drug pricing and product data misreporting by manufacturers. The proposed rule also includes several other program integrity and program administration provisions. Comments are due to the Centers of Medicare & Medicaid Services (CMS) by 2 p.m. (PT) on July 25 and can be submitted online.
CHA Comments on Proposed Payment Model to Lower Prescription Drug Costs
CHA has submitted comments to the Center for Medicare & Medicaid Innovation in response to its anticipated Accelerating Clinical Evidence (ACE) model.